Regarding additional potential biomarkers of aggressive HBL, Zhou and colleagues examined 277 with altered expression in HBL patients and discovered that TNFRSF19 is highly upregulated and could be used as an HBL biomarker [22]. The gene discussed is TNFRSF19; the disease is hepatoblastoma.